Community News

This page is dedicated to keeping you up to date on the latest SCN2A news and studies. Here you will be able to explore the latest articles, contribute to community posts, read other people’s stories, and much more. 

  • Young child reaching towards the sunny sky
    Young child reaching towards the sunny sky

    Your Voice Is Important

    At Praxis, we believe that if families and caregivers are a part of the research and development process it will improve our chances to successfully deliver a potentially disease-modifying treatment to patients with mutations in the SCN2A gene.

    Read More >
  • Young child reaching towards the sunny sky
    Young child reaching towards the sunny sky

    FDA Grants Praxis ODD for PRAX-562 for the Treatment of SCN2A-DEE

    On Wednesday, April 28, Praxis was granted orphan-drug designation (ODD) by the FDA for PRAX-562 for “treatment of SCN2A developmental and epileptic encephalopathy."

    Read More >
  • Young child reaching towards the sunny sky
    Young child reaching towards the sunny sky

    Thank You SCN2A Community

    We would like to extend our sincere gratitude to SCN2A community members who joined us for our virtual community discussions in March. We hope you found the information helpful.

    Read More >
  • Young child reaching towards the sunny sky
    Young child reaching towards the sunny sky

    Upcoming SCN2A Virtual Event: An introduction to Praxis, exploring potential treatments for the SCN2A community

    Like you, we at Praxis Precision Medicines (Praxis) envision a future where there is greater understanding of SCN2A-related gene mutations and better treatments to help the children and families affected by this rare disorder.

    Read More >
  • Young child reaching towards the sunny sky
    Young child reaching towards the sunny sky

    Praxis and The Florey Institute Collaborate on Innovative SCN2A Research

    Exciting news for the SCN2A community! Praxis has recently entered into an innovative research collaboration with The Florey Institute of Neuroscience and Mental Health.

    Read More >
  • Praxis SCN2A Awareness Day Team Photo
    Praxis SCN2A Awareness Day Team Photo

    Honoring International SCN2A Awareness Day

    At Praxis, we honor International #SCN2A Awareness Day and remain committed to providing therapies for patients as efficiently as possible.

    Read More >
  • Young child reaching towards the sunny sky
    Young child reaching towards the sunny sky

    Praxis Precision Medicines Partners With Ciitizen To Improve Patient-Guided Drug Development 

    Innovative collaboration to be implemented across multiple indications starting with SCN2A-DEE

    Read More >
  • Young child reaching towards the sunny sky
    Young child reaching towards the sunny sky

    Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations For Severe Pediatric Epilepsy Programs

    FDA grants RPD and ODD for PRAX-222 for treatment of SCN2A-DEE FDA grants RPD for PRAX-562 for treatment of SCN2A-DEE and SCN8A-DEE

    Read More >